Efficacy of Nipocalimab, a Novel Neonatal Fragment Crystallizable Receptor Blocker, as Measured Using Quantitative Myasthenia Gravis Assessment: Findings from the Phase 3 Placebo-controlled Vivacity-MG3 Study (S34.001)
To assess efficacy of nipocalimab using Quantitative Myasthenia Gravis (QMG) in patients with generalized myasthenia gravis (gMG).
Authors
- Sindhu Ramchandren (ORCID: https://orcid.org/0000-0002-5201-9200)
- Maria Ait-Tihyaty
- Ibrahim Turkoz (ORCID: https://orcid.org/0000-0003-1891-2297)
- Kavita Gandhi (ORCID: https://orcid.org/0000-0002-4521-2467)
- Richard M. Nowak (ORCID: https://orcid.org/0000-0002-7453-9426)
Institutions
- Yale University (US)
- Janssen (United States) (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211114
- Primary Topic
- S100 Proteins and Annexins
- Type
- article
- Field-Weighted Citation Impact
- 0.00